Logo image of MIST

MILESTONE PHARMACEUTICALS IN (MIST) Stock Price, Quote, News and Overview

NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD

0.8889  +0.07 (+8.8%)

After market: 0.871 -0.02 (-2.01%)

MIST Quote, Performance and Key Statistics

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (4/17/2025, 8:00:00 PM)

After market: 0.871 -0.02 (-2.01%)

0.8889

+0.07 (+8.8%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High2.75
52 Week Low0.63
Market Cap47.42M
Shares53.35M
Float51.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/bmo
IPO05-09 2019-05-09


MIST short term performance overview.The bars show the price performance of MIST in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

MIST long term performance overview.The bars show the price performance of MIST in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of MIST is 0.8889 USD. In the past month the price decreased by -54.42%. In the past year, price decreased by -45.8%.

MILESTONE PHARMACEUTICALS IN / MIST Daily stock chart

MIST Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 64.61 796.27B
JNJ JOHNSON & JOHNSON 15.67 379.48B
NVO NOVO-NORDISK A/S-SPONS ADR 16.83 257.82B
NVS NOVARTIS AG-SPONSORED ADR 13.96 218.96B
AZN ASTRAZENECA PLC-SPONS ADR 16.29 209.55B
MRK MERCK & CO. INC. 10.21 196.28B
PFE PFIZER INC 7.12 125.57B
SNY SANOFI-ADR 11.41 124.61B
BMY BRISTOL-MYERS SQUIBB CO 43.18 100.17B
GSK GSK PLC-SPON ADR 8.32 72.88B
ZTS ZOETIS INC 25.11 66.32B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.98 46.47B

About MIST

Company Profile

MIST logo image Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Company Info

MILESTONE PHARMACEUTICALS IN

420-1111 boul. Dr.-Frederik-Philips

MONTREAL QUEBEC H4M 2X6 CA

CEO: Joseph Oliveto

Employees: 47

Company Website: https://www.milestonepharma.com

Investor Relations: http://investors.milestonepharma.com

Phone: 15143360444

MILESTONE PHARMACEUTICALS IN / MIST FAQ

What is the stock price of MILESTONE PHARMACEUTICALS IN today?

The current stock price of MIST is 0.8889 USD. The price increased by 8.8% in the last trading session.


What is the ticker symbol for MILESTONE PHARMACEUTICALS IN stock?

The exchange symbol of MILESTONE PHARMACEUTICALS IN is MIST and it is listed on the Nasdaq exchange.


On which exchange is MIST stock listed?

MIST stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MILESTONE PHARMACEUTICALS IN stock?

10 analysts have analysed MIST and the average price target is 9.95 USD. This implies a price increase of 1018.8% is expected in the next year compared to the current price of 0.8889. Check the MILESTONE PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MILESTONE PHARMACEUTICALS IN worth?

MILESTONE PHARMACEUTICALS IN (MIST) has a market capitalization of 47.42M USD. This makes MIST a Nano Cap stock.


How many employees does MILESTONE PHARMACEUTICALS IN have?

MILESTONE PHARMACEUTICALS IN (MIST) currently has 47 employees.


Should I buy MILESTONE PHARMACEUTICALS IN (MIST) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MILESTONE PHARMACEUTICALS IN (MIST) stock pay dividends?

MIST does not pay a dividend.


When does MILESTONE PHARMACEUTICALS IN (MIST) report earnings?

MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2025-05-12, before the market open.


What is the Price/Earnings (PE) ratio of MILESTONE PHARMACEUTICALS IN (MIST)?

MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).


What is the Short Interest ratio of MILESTONE PHARMACEUTICALS IN (MIST) stock?

The outstanding short interest for MILESTONE PHARMACEUTICALS IN (MIST) is 1.46% of its float. Check the ownership tab for more information on the MIST short interest.


MIST Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MIST Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MIST Financial Highlights

Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 50.43% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -54.99%
ROE -315.81%
Debt/Equity 4.06
Chartmill High Growth Momentum
EPS Q2Q%37.81%
Sales Q2Q%N/A
EPS 1Y (TTM)50.43%
Revenue 1Y (TTM)-100%

MIST Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to MIST. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners42.61%
Ins Owners0.66%
Short Float %1.46%
Short Ratio0.7
Analysts
Analysts80
Price Target9.95 (1019.36%)
EPS Next Y-88.75%
Revenue Next YearN/A